Rigosertib
- Generic Name
- Rigosertib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C21H25NO8S
- CAS Number
- 592542-59-1
- Unique Ingredient Identifier
- 67DOW7F9GL
- Background
Rigosertib has been used in trials studying the treatment and basic science of MDS, RAEB, Cancer, Hepatoma, and Neoplasms, among others.
- Associated Conditions
- -
- Associated Therapies
- -
Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors
- Conditions
- Interventions
- First Posted Date
- 2023-03-10
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 29
- Registration Number
- NCT05764395
- Locations
- 🇺🇸
Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States
Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line Treatment
- Conditions
- Interventions
- First Posted Date
- 2020-02-10
- Last Posted Date
- 2024-05-09
- Lead Sponsor
- Icahn School of Medicine at Mount Sinai
- Target Recruit Count
- 25
- Registration Number
- NCT04263090
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia
- Conditions
- Interventions
- First Posted Date
- 2016-04-07
- Last Posted Date
- 2020-08-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 3
- Registration Number
- NCT02730884
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA
- First Posted Date
- 2015-09-29
- Last Posted Date
- 2022-09-26
- Lead Sponsor
- Traws Pharma, Inc.
- Target Recruit Count
- 372
- Registration Number
- NCT02562443
- Locations
- 🇺🇸
New York Medical College, Valhalla, New York, United States
🇺🇸USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States
Three Dosing Schedules of Oral Rigosertib in MDS Patients
- First Posted Date
- 2014-03-03
- Last Posted Date
- 2020-07-01
- Lead Sponsor
- Traws Pharma, Inc.
- Registration Number
- NCT02075034
- Locations
- 🇺🇸
Columbia University Medical Center, New York, New York, United States
Metabolism and Excretion of [14C]-Rigosertib After Infusion to Volunteers
- First Posted Date
- 2014-01-08
- Last Posted Date
- 2017-06-23
- Lead Sponsor
- Traws Pharma, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT02030639
- Locations
- 🇺🇸
Covance Clinical Research Unit, Inc., Madison, Wisconsin, United States
Oral Rigosertib for Squamous Cell Carcinoma
- First Posted Date
- 2013-03-08
- Last Posted Date
- 2017-06-26
- Lead Sponsor
- Traws Pharma, Inc.
- Target Recruit Count
- 64
- Registration Number
- NCT01807546
- Locations
- 🇺🇸
Blue Ridge Cancer Care, Salem, Virginia, United States
🇺🇸Stanford Cancer Institute, Stanford, California, United States
🇺🇸Mount Sinai Medical Center, New York, New York, United States
Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome
- First Posted Date
- 2012-04-25
- Last Posted Date
- 2017-06-26
- Lead Sponsor
- Traws Pharma, Inc.
- Target Recruit Count
- 82
- Registration Number
- NCT01584531
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
🇺🇸Columbia University Medical Center, New York, New York, United States
Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL)
- Conditions
- Interventions
- First Posted Date
- 2010-07-22
- Last Posted Date
- 2017-06-26
- Lead Sponsor
- Traws Pharma, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT01167166
- Locations
- 🇺🇸
University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States
Safety, Pharmacokinetics and Clinical Activity of Oral Rigosertib in Solid Tumors
- First Posted Date
- 2010-07-22
- Last Posted Date
- 2017-06-23
- Lead Sponsor
- Traws Pharma, Inc.
- Target Recruit Count
- 68
- Registration Number
- NCT01168011
- Locations
- 🇺🇸
University of Colorado at Denver Health and Sciences, Denver, Colorado, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.